Kontakt

Lindhagensgatan 120
Box 30052
104 25 Stockholm
Sverige
Telefon: 08-634 50 00
Kontakta oss

Referenser och kliniska studier

  • Skriv ut
  • Larger Smaller

    Teckenstorlek

  • Uppdaterad : 2018-04-24

1. Swedeheart Årsrapport 2015

2. LaRosa JC, et al. N Engl J Med. 2005;352:1425–35

3. Karalis DG, et al. Cholesterol. 2012;2012:1–7

4. Reiner Ž, et al. Eur Heart J. 2011;32:1769–18

5. Hamilton-Craig I, et al. Vasc Health Risk Manag. 2010;6:1023–37

6. Cannon CP, et al. N Engl J Med. 2004;350(15):1495–04

7. Pedersen TR, et al. JAMA. 2005;294:2437–45

8. Parker BA, et al. Circulation. 2013;127:96–103

9. Ganga H, et al. Am Heart J. 2014;168:6–15

10. Nordestgaard BG, et al. Eur Heart J. 2013:34;3478–90

11. Yusuf S, et al. Lancet 2004;364:937–52

12. Pöss J, et al. Curr Pharm Des. 2011;17:861–70

13. Arca M, et al. Diabetes Metab Syndr Obes. 2011;4:155–66

14. Pijlman AH. Atheros 2010;209:189–94

15. Jernberg T, et al. Eur Heart J. 2015;13 jan:Epub ahead of print

16. Clin Ther. 2015 Aug 14. pii: S0149-2918(15)00936-4. doi:10.1016/j.clinthera.2015.07.008. [Epub ahead of print] Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Roth EM1, Bujas-Bobanovic M2, Louie MJ3, Cariou B4

17. Robinson JG, Farnier M, Krempf M, et al, for the ODYSSEY LONG TERM Investigators. Efficacy and safe­ty of PRALUENT in reducing lipids and cardiovascular events [published online ahead of print March 15, 2015]. N Engl J Med. doi:10.1056/NEJMoa1501031

18. Cannon CP, Cariou B, Blom D, et al, for the ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial [published online ahead of print February 16, 2015]. Eur Heart J. doi:10.1093/eurheart/ehv028

19. PRALUENT produktresumé 2015

20. Peter H. Jones; Harold Bays; Umesh Chaudhari; Robert Pordy; Christelle Lorenzato; Kathryn Miller; Jennifer Robinson, J Am Coll Cardiol. 2015;65(10_S). doi:10.1016/S0735- 1097(15)61363-8

21. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.